RE: Directors2 Dec 2022 23:47
They need to cut staffing levels , yet again, to survive I feel ....so I doubt if they will do that before Christmas . The directors made enough dosh when Abingdon went public so they can easily reinvest to show some support and try to bolster up the share price .
The problem for me is the competition from China ,
they can't compete on price . Abingdon's strength is their expertise in developing new tests but it all takes time and unfortunately three of their projects that they bought to the market have failed and the majority of their pipeline is now on hold plus they are running out of cash . I can't see how this business is going to start to recover any time soon .